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Abstract
Background: The treatment of patients with malignant brain tumors remains a major oncological problem. The
median survival of patients with glioblastoma multiforme (GBM), the most malignant type, is only 15 months after
initial diagnosis and even less after tumor recurrence. Improvements of standard treatment including surgery and
radio-chemotherapy have not lead to major improvements. Therefore, alternative therapeutics such as oncolytic
viruses that specifically target and destroy cancer cells are under investigation. Preclinical data of oncolytic
parvovirus H-1 (H-1PV) infection of glioma cells demonstrated strong cytotoxic and oncosuppressing effects,
leading to a phase I/IIa trial of H-1PV in patients with recurrent GBM (ParvOryx01). ParvOryx01 is the first trial with a
replication competent oncolytic virus in Germany.
Methods: ParvOryx01 is an open, non-controlled, two groups, intra-group dose escalation, single center, phase I/IIa
trial. 18 patients with recurrent GBM will be treated in 2 groups of 9 patients each. Treatment group 1 will first
receive H-1PV by intratumoral injection and second by administration into the walls of the tumor cavity during
tumor resection. In treatment group 2 the virus will initially be injected intravenously and afterwards, identical to
group 1, into the surrounding brain tissue during tumor removal. Main eligibility criteria are: age of 18 years,
unifocal recurrent GBM, amenable to complete or subtotal resection. Dose escalation will be based on the
Continual Reassessment Method. The primary objective of the trial is local and systemic safety and tolerability and
to determine the maximum tolerated dose (MTD). Secondary objectives are proof of concept (PoC) and
Progression-free Survival (PFS) up to 6 months.
Discussion: This is the first trial with H-1PV in patients with recurrent GBM. The risks for the participants appear
well predictable and justified. Furthermore, ParvOryx01 will be the first assessment of combined intratumoral and
intravenous application of an oncolytic virus. Due to its study design the trial will not only generate data on the
local effect of H-1PV but it will also investigate the penetration of H-1PV into the tumor after systemic delivery and
obtain safety data from systemic delivery possibly supporting clinical trials with H-1PV in other, non-CNS
malignancies.
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Background
According to the estimation of the American Cancer
Society about 16,000 new cases of intracranial neoplasm
are diagnosed in the USA each year, being over half the
number of new cases of melanoma [1]. The largest
group with approximately 12,700 new cases per year are
gliomas, primary central nervous system neoplasms with
characteristics of neuroglial cells. Of those the most fre-
quent subgroup with more than 6,000 new diagnoses
per year is glioblastoma multiforme (GBM), which is
also the most malignant type of gliomas. The incidence
of GBM is currently showing a slight but relevant
increase [2]. The majority of patients diagnosed with
GBM is over 40 years of age [1].
Despite different therapeutic approaches and their
recent progress, the treatment options for patients suf-
fering from glioblastoma are still disappointing. The
overall survival rates amounted to 33, 12, 7, 5, and 4 per
cent after 1, 2, 3, 4, and 5 years, respectively [3]. The
1-year PFS was as low as 10% in individuals presenting
recurrent disease and treated solely with chemotherapy
[4]. At present, established therapeutic strategies include
surgery, radiation, chemotherapy, and molecular tar-
geted agents. New approaches are on the way [5].
Amongst other experimental therapies, oncolytic
viruses are investigated for treatment of high-grade glio-
mas. Several candidates such as HSV-1, adenovirus, New-
castle disease virus, reovirus, poliovirus, and vaccinia
virus were identified to have toxic effects on glioma cells
[6]. Up to now several clinical trials were carried out to
demonstrate the safety and in part efficacy of the viral
candidates in patients suffering from recurrent malignant
gliomas [7-11]. All viruses were administered either
intratumorally or intracerebrally into the walls of the
resection cavity. A good tolerability and no safety issues
could be observed throughout the trials. If applicable, the
dose escalation could be performed according to the pre-
defined schedule.
Trial rationale/justification
Agents that possess anti-glioma activity, a tolerable
safety profile and no unjustified risk for the general
population should undergo rapid development to assess
their therapeutic potential.
Parvovirus H-1 (H -1PV) is a small single-stranded
rodent DNA virus. The natural host is rat but H-1PV is
able to infect and replicate in cells of various other spe-
cies including humans. Parvoviruses are unique among
DNA viruses as they do not have any tumorigenic mem-
bers [12]. In contrast, some parvoviruses exert cyto-
pathic effects, mainly in neoplastic cells [13] and they
have been shown to possess oncosuppressive properties
[14,15]. In general, parvovirus H-1 is classified as non
pathogenic.
A strong oncolytic effect was shown in different estab-
lished glioblastoma cell lines of rat and human origin
and in short-term/low-passage cultures of human glio-
blastoma cells, at low multiplicities of infection (MOI)
[16]. Infection of glioma cells with H-1PV virus yielded
progeny H-1PV virions in all cultures, however with
marked differences of titers. In conclusion, malignant
glial cells appear to represent a highly susceptible target
for H-1PV virus-mediated cytotoxicity. Furthermore,
H-1PV was shown to activate a non-conventional, cathe-
psin-mediated death pathway, leading to cell killing also
in glioma cells that are frequently resistant to apoptotic
cell death mechanisms [17].
In orthotopic glioma models in rats large tumors (> 6
mm) were either injected stereotactically with H-1PV
(single intratumoral injection) or H-1PV was adminis-
tered by multiple intravenous injections (systemic
route). H-1PV virus treatment resulted in rapid tumor
regression and significant prolongation of survival of
treated animals [18]. Histological analysis showed wide-
spread destruction of tumor tissue, without any toxic or
inflammatory side effects in the surrounding brain tis-
sue. Virus replication was demonstrated in tumors, indi-
cating a contribution of secondary infection by progeny
virus to the efficiency of oncolysis. Hence, complete
remission of advanced intracranial gliomas by oncolytic
parvovirus H-1PV could be achieved showing that
H-1PV possesses strong anti-tumor activity also in vivo.
Based on the findings described above, H-1PV may be
reasonably assumed to be effective for treatment of glio-
blastoma in humans. Moreover, the virus offers some
potential advantages over the current therapeutic
modalities:
Unlike other oncolytic viruses, H-1PV was shown to
cross the blood-brain barrier and to infect intracerebral
tumors. This offers the chance of boosting the initial
local therapy by consecutive intravenous administrations
or for interval retreatment without the necessity of
craniotomy.
H-1PV may potentially evoke an anticancer vaccination
effect based on release of tumor-associated antigens and
subsequent immunostimulation. This could lead to long-
term effects in prevention of disease relapse, potentially
adding to initial oncolysis.
Taken together, the therapy with H-1PV as planned in
this protocol may provide considerable benefit for
included subjects. Furthermore, the findings from the
trial are crucial for consecutive clinical development of
H-1PV for glioblastoma and other tumor entities.
Design and methods
Aim
This trial aims to investigate the safety, biodistribution,
maximum tolerated dose and signs of anti-tumor
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activity of parvovirus H-1 in patients suffering from
recurrent malignant gliomas. According to preclinical
data and differing from previous oncolytic virus trials in
GBM patients ParvOryx01 will not only include intratu-
moral virus application but also intravenous treatment.
Objectives
Primary objectives
The primary objective of the trial is related to the safety
and tolerability of the Investigational Medicinal Product
(IMP). The particular parameters for this objective are:
• Local and systemic safety and tolerability of intratu-
moral/intracerebral and intravenous/intracerebral
administration of the IMP,
• Maximum tolerated dose (MTD) of the IMP as
assessed by NCI CTCAE v4.0,
• Viremia following intratumoral, intracerebral and
intravenous administration of the IMP,
• IMP shedding/persistence following intratumoral,
intracerebral and intravenous administration of the IMP.
Secondary objectives
The secondary objective of the study is related to the
efficacy of the IMP. The particular parameters for this
objective are:
• Evidence for anti-tumor activity of the IMP in sub-
jects with recurrent GBM (Proof of Concept, PoC),
• Progression-free Survival (PFS) up to 6 months after
study inclusion,
• Overall survival (OS) up to 6 months after study
inclusion.
Design
Parvoryx01 is an open, non-controlled, two groups,
intra-group dose escalation, single center study.
Due to the exploratory approach of the current trial
with regard to safety and tolerability of the IMP no
positive control will be used. The implementation of a
negative control (placebo) is ethically unjustifiable in
subjects suffering from rapid progressive disease who
otherwise can undergo a potentially effective treatment.
The safety and tolerability of the IMP will be investi-
gated after both, local, i.e. intratumoral/intracerebral and
systemic, i.e. intravenous administration. Therefore, two
separate study groups representing both modes of
administration will be examined. Since the trial is the
first-in-man study of the IMP, the dose escalation will be
carried out in accordance to a sequential escalating
design, including interims assessments of safety and tol-
erability after each dose level and between both study
groups.
Due to the complex handling and administration of the
IMP this first trial will be performed in a single center
under coordination of an investigator who possesses pro-
found knowledge of all aspects concerning the IMP.
Eligibility
Patients have to suffer from progressive primary or
recurrent glioblastoma multiforme (GBM) scheduled for
neurosurgery, i.e. for a complete or subtotal tumor
resection. Patients have to fulfill the following main
inclusion crieteria: (i) 18 years of age or older, (ii) con-
firmed diagnosis of glioblastoma multiforme (WHO
grade IV), (iii) recurrence or tumor progression despite
previous radio- and/or chemotherapy, (iv) life expec-
tancy of at least 3 months, (v) Karnofsky Performance
Score ≥60, (vi) commitment to omit exposure to infants
< 18 months of age or immunocompromised individuals
for up to 28 day after first administration of IMP.
Main criteria to exclude subjects from the trial are (i)
multifocal disease, (ii) evidence of distant tumor metas-
tases, (iii) contraindications for MRI, (iv) treatment with
antiangiogenic substances within 21 days prior to ther-
apy, (v) radiotherapy within 90 days prior to study inclu-
sion, (vi) chemotherapy within 4 weeks prior to study
inclusion.
Sample size
The current trial represents the first in man study with the
IMP (ParvOryx). 18 subjects will be allocated to 2 study
groups with 9 subjects per group. Per group, 3 dose levels
will be investigated. The mean number of 3 subjects per
dose level appears to be sufficient to give first indications
about safety, tolerability and proof of concept of ParvOryx.
There will be no a-priori defined quantitative ratio
between females and males. However, no gender differ-
ences in the safety, tolerability as well as efficacy are
expected on the basis of preclinical findings.
Course of the trial
For each patient the ParvOryx01- trial includes two
phases: i) the screening phase in which eligibility for trial
inclusion is assessed and ii) the treatment/follow-up phase
in which the trial treatment, the medical monitoring and
3 follow-up visits are performed. Due to the rapid growth
of recurrent glioblastomas and the limited capacity for fast
consecutive study inclusion according to safety regula-
tions, patients have to be continuously screened while
other patients are already under treatment. Therefore,
screening phase and treatment phase are overlapping.
Screening phase
Screening of patients has to be performed within 2 weeks
prior to study inclusion. Potentially eligible patients are
provided with comprehensive written and verbal informa-
tion. Investigations that are carried out during the screen-
ing procedure include:
Written informed consent, demography and medical
history, physical and neurological examination, vital signs
and 12-lead ECG, clinical chemistry, hematology and clot-
ting, serum protein electrophoresis, MRI, viral shedding of
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H-1 PV in blood, urine, stool and throat swabs, H-1 PV
specific antibodies, HIV, HBV and HCV serology, preg-
nancy test.
At discretion of a responsible investigator patients in
group II can be required to undergo a stereotactic
biopsy and sampling of a tumor specimen for histologi-
cal confirmation of GBM by a neuropathologist (only, if
in opinion of the investigator the evidence of glioblas-
toma recurrence is not sufficient).
Intervention
The IMP for this trial is ParvOryx, a GMP-grade prepara-
tion of Parvovirus H-1. The application of the IMP will be
performed in 2 groups of 9 patients each. The route of
administration differs between group 1 and group 2
(Figure 1). Within each group the mode of application is
identical, but the dose will be increased if no dose limiting
events are observed. In each group the IMP will be admi-
nistered in three dose levels (Table 1)
In group 1 the patients will receive the IMP on day 1
via image guided injection into the tumor tissue. On
this day the patient is injected with 50% of the intended
overall dose. After an observation period of 9 days the
tumor will be resected on day 10. After tumor removal
the second half of the dose will be administered into the
walls of the resection cavity by direct injection. With
this injection during open surgery the administration of
the IMP is completed and no additional virus applica-
tion will be performed.
In group 2 the initial administration of the IMP is via
the intravenous route. Subjects receive 50% of the
intended dose by 5 infusions on days 1 to 5, each infu-
sion containing 10% of the total dose. After the last
infusion on day 5 there is an observation period until
day 9 and on day 10 tumor resection will be performed
as in group 1. In analogy to group 1, patients receive
the second half of the dose by injection in the tissue
surrounding the tumor cavity after tumor removal and
no further virus injections will be performed in each
individual during the course of the trial.
Trial schedule and duration
As ParvOryx01 is a first in man trial with administration
of a replication competent parvovirus the recruitement
schedule for the trial is strictly regulated. Prior to the
treatment of the 2nd subject of each dose level data from
the 1st subject of this level will be collected up to day 28.
Similarly, prior to the treatment of the 3rd subject of a
Figure 1 Schematic diagram of the ParvOryx01 trial: study group 1 will be treated first. After completion of group 1 an interim analysis
will be performed prior to recruiting patients for study group 2. Information about dose escalation is specified in Table 1.
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dose level data from the 2nd subject up to day 18 will be
collected. The 2nd and 3rd subject will only undergo treat-
ment with the IMP if no unjustifiable adverse reactions
occurred previously. The decision will be made by mutual
agreement between the principal investigator or another
responsible investigator and the sponsor. After completion
of a dose level the data safety monitoring board (DSMB)
has to give consent to move to the next dose level. A deci-
sion regarding the progress to the 2nd study group will be
based on agreement between DSMB, principal investigator
and sponsor after review of selected data from 1st study
group obtained up to Day 28. The information obtained
from 1st study group will be provided to the Competent
Authority (Paul-Ehrlich-Institute) for a review. A progress
to the 2nd study group will only take place if there is no
objection of the Competent Authority.
The per-subject trial duration including all follow-up
visits will be 6 months. After the end of the main treat-
ment phase on day 28, 3 follow-up visits will be performed
at 2, 4 and 6 months after trial inclusion. The overall dura-
tion of the clinical trial, including completion of all follow-
up visits related to the efficacy of the IMP in all subjects,
is scheduled to last approximately 24 months.
The treatment phase and the capture of data on the
safety and tolerability of the IMP (primary objective) will
be completed approximately 18 month after inclusion of
the 1st study subject. The per-subject trial duration as
related to the primary objective will last 28 days.
It can be assumed that the treatment and the documen-
tation of the primary objective parameters in one dose
escalation level will take approximately 3 months.
Specific hygienic measures
Due to the first in man application of a replication com-
petent parvovirus and the lack of data about the toxicity
and excretion of the IMP in humans after intracerebral
or intravenous injection specific procedures have to be
applied. Despite low hygienic risks associated with the
current trial a number of hygienic measures have to be
adhered to (Table 2).
Benefit/risk assessment
Currently, recurrent glioblastoma is a tumor entity for
which no established standard of care exists. The prog-
nosis of this disease is dismal, the progression free survival
at 6 months (6 M-PFS) ranges between 15% to 21% and
the median survival of patients is in the range of 25 weeks
[19]. Re-operation is one possible treatment option with
proven clinical benefit. It can be estimated that one third
of patients with recurrent GBM are candidates for a
second debulking surgical procedure.
Non-surgical treatment options include the application
of re-irradiation for a subset of approximately 20% of
patients and the use of chemotherapy. None of these
treatments has been shown to have a major impact on
PFS or survival.
The use of replication competent Parvovirus H-1 in the
current trial setting therefore addresses a patient popula-
tion without a standard of care and with only limited
treatment options. According to the study protocol even
without oncolytic efficacy of H-1PV patients would bene-
fit from participating in the trial due to re-operation after
initial virus treatment.
Table 1 Dose schedule for both study groups
GROUP I
Escalation Level Study Time Dose and route of administration Duration
Level 1 Total dose: 1 × 106 pfu Day 1 5 × 105 pfu, intratumoral (via catheter) 15 minutes
Day 10 5 × 105 pfu, intracerebal (direct injection at multiple locations of resection wall) 15-30 minutes
Level 2 Total dose: 5 × 107 pfu Day 1 2.5 × 107 pfu, intratumoral (via catheter) 15 minutes
Day 10 2.5 × 107 pfu, intracerebal (direct injection at multiple locations of resection wall) 15-30 minutes
Level 3 Total dose: 1 × 109 pfu Day 1 5 × 108 pfu, intratumoral (via catheter) 15 minutes
Day 10 5 × 108 pfu, intracerebral (direct injection at multiple locations of resection wall) 15-30 minutes
GROUP II
Escalation Level Study Time Dose and Route of Administration Duration
Level 1 Total dose: 1 × 106 pfu Day 1 - 5 1 × 105 pfu, intravenous infusion 2 hours
Day 10 5 × 105 pfu, intracerebral (direct injection at multiple locations of resection wall) 15-30 minutes
Level 2 Total dose: 5 × 107 Day 1 - 5 0.5 × 107 pfu, intravenous infusion 2 hours
Day 10 2.5 × 107 pfu, intracerebral (direct injection at multiple locations of resection wall) 15-30 minutes
Level 3 Total dose: 1 × 109 pfu Day 1 - 5 1 × 108 pfu, intravenous infusion 2 hours
Day 10 5 × 108 pfu, intracerebral (direct injection at multiple locations of resection wall) 15-30 minutes
Specification of virus application and dose escalation during the Parvoryx01 trial: dose group 2 will be treated after completion of group 1 and after interim
analysis of safety and tolerability in group 1.
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There is only limited information about the effects of
Parvovirus H-1 infections of humans, but according to
the assessment of the pathogenicity of the virus in
humans by the Robert Koch Institut it is classified as
non-pathogenic in man. This is supported by the limited
available information from human patients. According to
data from Parvovirus H-1 application in terminally ill
tumor patients in 1965 and in 1993 the injection(s) did
not cause severe side effects. The virus that was used in
these patients (n = 2 in 1965 and n = 12 in 1993) was not
produced according to today’s GMP standard and the
amount of virus that was injected was in the range from
approx. 2 × 10 exp8 to approx. 3 × 10 exp10 [20,21].
Recently, it could also be demonstrated that even labora-
tory staff who had worked with Parvovirus H-1 for sev-
eral years was tested negative for Parvovirus H-1 specific
antibodies, ruling out active infection and pointing to a
very low level of contagiousness of H-1PV in humans
(Jörg R. Schlehofer, German Cancer Research Center
(DKFZ), personal communication).
The virus batch that was produced under GMP condi-
tions for use in this clinical trial was tested extensively in
animals to obtain toxicology data. Toxicology testing
included intravenous and intracerebral administrations.
In the repeat dose toxicology study multiple intravenous
injections over a 28 day period at 3 different dose levels
(low, medium, high) were employed. The only safety
issue diagnosed by histology but not by clinical or labora-
tory abnormalities was a minimal bile duct proliferation
observed in some animals of the highest and in one ani-
mal of the middle dose group after repeated applications.
No other relevant pathological findings that could be
attributed to H-1PV were observed, confirming that even
multiple injections of high virus titers are not associated
with severe side effect. Thus, injection of H-1PV accord-
ing to this trial protocol can be assumed to possesses
only a low risk of side effects in patients with a life threa-
tening disease.
Due to the lack of relevant pathogenicity of H-1PV in
humans, viral shedding by injected patients with subse-
quent symptomatic infections of unrelated subjects is
extremely unlikely. In addition, patients will be isolated
after virus treatment until no virus shedding can be
demonstrated by real-time PCR or virus specific antibo-
dies are present. This in combination with specific
hygiene precautions further minimizes the risk for the
environment and for hospital staff or other subjects.
Statistical analysis
Analysis variables
The primary criterion for dose modification is the relative
frequency of a dose-limiting event (DLE) at a given dose
level. Toxicity of a dose is defined as the probability of
this dose being associated with a DLE in a patient as indi-
cated in the trial protocol. A dose is defined as tolerable
if the probability of toxicity is lower than 33 per cent.
The maximum tolerated dose is defined as the dose level
with the highest posterior probability of having a toxicity
not higher than 33 per cent.
Statistical methods
The posterior probability for toxicity will be calculated
in a logistic model, where the toxicities are parame-
trized as follows: pij: toxicity for group i, level j,
log(pi1/(1 − pi1)) = ai − βi; log(pi2/(1 − pi2)) = ai log(pi3/(1 − pi3)) = ai + βi;
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Table 2 Specific hygenic measures
• Information of staff involved in the medical care/nursing of trial subjects (e.g. physicians, nurses, cleaning staff, physiotherapist),
• Proposal of serological testing of medical staff for H-1PV prior to the beginning and at the end of the trial (in order to document potential
seroconversion),
• Consideration of a subject as potentially viremic until:
○ A seroconversion as proven by HIT or ELISA,
○ In the absence of a seroconversion until proven lack of virus shedding in urine, saliva, and feces,
• While a subject is considered as potentially viremic:
○ Isolate her/him in a single room with its own toilet,
○ Use disposable gloves, protection gown and mask for handling of study medication and
materials contaminated with ParvOryx, e.g. infusion materials,
○ Information of medical staff to use gloves, protection gown and mask when in physical contact with the patient,
○ Information of medical staff and visitors to use mask only when strictly omitting body contact with the subject during his/her isolation phase.
Alternatively, the subject can wear a mask when in the same room with medical staff and visitors,
○ Information of hygiene staff to carry out a terminal disinfection after discharge of a subject from isolation,
○ In case of surface contamination the disinfection must be performed with Perform®, 3%
ParvOryx01 is the first in man application of a GMP grade oncolytic parvovirus. The hygienic precautions listed above must be applied including isolation of
patients in a single room as long as they are considered viremic. Virus shedding and seroconversion are tested daily to reduce duration of isolation to a
minimum
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Whenever a subject enters the study, the dose level
will be elicited by calculating the posterior probability
for each dose level to be tolerable. The highest dose
level that is tolerable will be allocated.
The following measurements will be subject to
descriptive statistical methods: vital signs, serum levels
and hematology data, H-1 PV specific antibodies, virus
shedding. Progression Free Survival and Overall Survival
will be listed per group and subject, showing observa-
tion time and event status.
Dose escalation scheme
As long as no DLE is observed, a classic three-at-one
design will be followed [22]. After the first DLE is
observed one more patient will be recruited at the same
dose before the dose will be determined as the maximum
tolerated dose following the model outlined above. The
highest dose with a median probability of tolerability being
at least 33 per cent will be applied as the current MTD to
the subsequent patient, following the Continual Reassess-
ment Method [23]. If the MTD is ever to be calculated as
being “dose 0”, the trial ends prematurely at any time with
the result that no safe dose could be established (Figure 2).
Nine consecutive patients will be allocated to Group 1
before nine more patients will be allocated to Group 2. As
the metaparameters a and b are assumed to be correlated
between groups, results from group 1 affect the escalation
scheme in group 2.
Discussion
The application of replication competent oncolytic
viruses is a promising approach to target dismal malig-
nancies such as glioblastoma multiforme. The ParvOryx
trial is the first in man application of oncolytic Parvovirus
H-1 produced to GMP standard. To our knowledge this
trial is the first clinical use of a replicating oncolytic virus
in Germany. The trial design combines major efforts to
assure safety with the chance to gain important informa-
tion about the biological activity of the virus from speci-
mens. Even though toxicological testing of the study
medication did not reveal any safety issues after intracer-
ebral or intravenous injection, the risk of side effects or
adverse events in patients has to be minimized. To meet
this demand the first 3 patients in both treatment groups
will receive a low virus dose and even within each dose
group patients can only be included after an extended
observation period of 28 days between patient 1 and 2
and 18 days between patient 2 and 3. This concept
should be capable of detecting major safety issues before
a subsequent individual gets under treatment. However,
long-term adverse events cannot be ruled out, but due to
the aggressive nature of the disease the remaining degree
of uncertainty seems justified. In this trial only patients
with resectable recurrent GBMs are included. For this
patient cohort the prognosis is very poor and there is no
established standard of care. Tumor resection is consid-
ered beneficial irrespective of subsequent therapies.
Therefore, the ParvOryx trial offers to patients the stan-
dard level of care by tumor removal in combination with
the chance of oncolytic activity of the IMP. The ParvOryx
trial is unique by not only including an intratumoral
treatment arm, which is standard for trials with oncolytic
viruses in GBM patients, but also an intravenous arm.
Due to the favourable biological properties of H-1PV this
trial protocol is able to reflect the possible advantage of a
combined oncolytic virus treatment with a high local
dose and the chance to infect remote tumor cells through
Figure 2 Dose escalation scheme of ParvOryx01 for the 1st study group. The numbers (1, 2, or 3) depict the dose level for the next patient.
Red arrows denote a dose limiting event in this patient and black arrows a patient tested without an event. Trial stops at the bottom line or
whenever a dose level of zero is reached.
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the blood stream. Through the intravenous arm the Par-
vOryx trial will also provide information that should
facilitate future clinical trials on non-CNS malignancies
in which intravenous treatment is a possible route of
administration.
Due to the use of an infectious albeit non-pathogenic
agent specific hygienic measures have to be taken. In con-
sequence, entering the trial will result in a temporary
reduced quality of life through the need for the patient to
be kept in isolation until viremia can be ruled out or sero-
conversion has occurred. The trial protocol takes this con-
straint into account by daily testing of specific probes
thereby keeping the duration of isolation to a minimum.
The environmental hazard of the treatment is considered
to be low as H-1PV is a naturally occurring and apatho-
genic virus that seems to be non-contagious for humans
unless directly injected. By strictly adhering to hygienic
precautions the conduct of the trial should not expose
others including medical staff to a relevant health risk.
The dose-finding scheme uses information from treat-
ment group 1 when eliciting the MTD in treatment
group 2. Furthermore, the final appreciation of tolerabil-
ity in group 1 will retroactively use results from group 2.
The rationale for this statistic approach is the assumption
that at least 0.1 per cent of the viral load applied intratu-
morally and/or intracerebrally will enter the peripheral
blood stream and the ratio between the lowest and the
highest dose is 1:1000.
Finally, it is highly appreciated that by entering the
trial subjects help to assess and further develop this
therapeutic concept.
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